Free fatty acid (FFA) and hydroxy carboxylic acid (HCA) receptors

Annual Review of Pharmacology and Toxicology

Volumn 54, Issue , 2014, Pages 407-434

  Offermanns, Stefan ^a,b  

^a MAX PLANCK INSTITUTE FOR HEART AND LUNG RESEARCH   (Germany)

^b GOETHE UNIVERSITY   (Germany)

Author keywords

Acetate; Ketone body; Lactate; Nicotinic acid; Polyunsaturated fatty acid; Short chain fatty acid

Indexed keywords

CARBOXYLIC ACID; FATTY ACID; FFA1 LIGAND; FFA1 RECEPTOR; FFA2 LIGAND; FFA2 RECEPTOR; FFA3 LIGAND; FFA3 RECEPTOR; FFA4 LIGAND; FFA4 RECEPTOR; G PROTEIN COUPLED RECEPTOR; HCA1 LIGAND; HCA1 RECEPTOR; HCA2 LIGAND; HCA2 RECEPTOR; HCA3 LIGAND; HCA3 RECEPTOR; LIGAND; LONG CHAIN FATTY ACID; SHORT CHAIN FATTY ACID; UNCLASSIFIED DRUG;

BIOLOGICAL FUNCTIONS; HOMEOSTASIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; FATTY ACIDS, NONESTERIFIED; HOMEOSTASIS; HUMANS; LIGANDS; MOLECULAR TARGETED THERAPY; OBESITY; RECEPTORS, G-PROTEIN-COUPLED; RECEPTORS, NICOTINIC;

EID: 84891859045     PISSN: 03621642     EISSN: 15454304     Source Type: Book Series    
DOI: 10.1146/annurev-pharmtox-011613-135945     Document Type: Review

References (207)

1. Bugaut M, Bentéjac M. 1993. Biological effects of short-chain fatty acids in nonruminant mammals. Annu. Rev. Nutr. 13:217-41
2. Nunez EA. 1997. Biological complexity is under the 'strange attraction' of non-esterified fatty acids. Prostaglandins Leukot. Essent. Fatty Acids 57:107-10
3. Briscoe CP, Tadayyon M, Andrews JL, Benson WG, Chambers JK, et al. 2003. The orphan G proteincoupled receptor GPR40 is activated by medium and long chain fatty acids. J. Biol. Chem. 278:11303-11
4. Brown AJ, Goldsworthy SM, Barnes AA, Eilert MM, Tcheang L, et al. 2003. The orphan G proteincoupled receptorsGPR41 and GPR43 are activated by propionate and other short chain carboxylic acids. J. Biol. Chem. 278:11312-19
5. Itoh Y, Kawamata Y, Harada M, Kobayashi M, Fujii R, et al. 2003. Free fatty acids regulate insulin secretion from pancreatic βcells through GPR40. Nature 422:173-76
6. Kotarsky K, Nilsson NE, Flodgren E, Owman C, Olde B. 2003. A human cell surface receptor activated by free fatty acids and thiazolidinedione drugs. Biochem. Biophys. Res. Commun. 301:406-10
7. Le Poul E, Loison C, Struyf S, Springael JY, Lannoy V, et al. 2003. Functional characterization of human receptors for short chain fatty acids and their role in polymorphonuclear cell activation. J. Biol. Chem. 278:25481-89
8. Nilsson NE, Kotarsky K, Owman C, Olde B. 2003. Identification of a free fatty acid receptor, FFA2R, expressed on leukocytes and activated by short-chain fatty acids. Biochem. Biophys. Res. Commun. 303:1047-52
9. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, et al. 2005. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat. Med. 11:90-94
10. Offermanns S, Colletti SL, Lovenberg TW, Semple G, Wise A, IJzerman AP. 2011. International Union of Basic and Clinical Pharmacology. LXXXII: Nomenclature and classification of hydroxy-carboxylic acid receptors (GPR81, GPR109A, and GPR109B). Pharmacol. Rev. 63:269-90
11. Cai TQ, Ren N, Jin L, Cheng K, Kash S, et al. 2008. Role of GPR81 in lactate-mediated reduction of adipose lipolysis. Biochem. Biophys. Res. Commun. 377:987-91
12. Liu C, Wu J, Zhu J, Kuei C, Yu J, et al. 2009. Lactate inhibits lipolysis in fat cells through activation of an orphan G-protein-coupled receptor, GPR81. J. Biol. Chem. 284:2811-22
13. Ahmed K, Tunaru S, Offermanns S. 2009. GPR109A, GPR109B and GPR81, a family of hydroxycarboxylic acid receptors. Trends Pharmacol. Sci. 30:557-62
14. Taggart AK, Kero J, Gan X, Cai TQ, Cheng K, et al. 2005. (D)-β-Hydroxybutyrate inhibits adipocyte lipolysis via the nicotinic acid receptor PUMA-G. J. Biol. Chem. 280:26649-52
15. Kebede MA, Alquier T, Latour MG, Poitout V. 2009. Lipid receptors and islet function: therapeutic implications? Diabetes Obes. Metab. 11(Suppl. 4):10-20
16. Blad CC, Tang C, Offermanns S. 2012. G protein-coupled receptors for energy metabolites as new therapeutic targets. Nat. Rev. Drug Discov. 11:603-19
17. Hara T, Hirasawa A, Ichimura A, Kimura I, Tsujimoto G. 2011. Free fatty acid receptors FFAR1 and GPR120 as novel therapeutic targets for metabolic disorders. J. Pharm. Sci. 100:3594-601
18. Hudson BD, Smith NJ, Milligan G. 2011. Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors. Adv. Pharmacol. 62:175-218
19. Oh DY, Lagakos WS. 2011. The role of G-protein-coupled receptors in mediating the effect of fatty acids on inflammation and insulin sensitivity. Curr. Opin. Clin. Nutr. Metab. Care 14:322-27
20. Shen HC, Colletti SL. 2009. Novel patent publications on high-affinity nicotinic acid receptor agonists. Expert Opin. Ther. Pat. 19:957-67
21. Stoddart LA, Smith NJ, Milligan G. 2008. International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions. Pharmacol. Rev. 60:405-17
22. Ulven T. 2012. Short-chain free fatty acid receptors FFA2/GPR43 and FFA3/GPR41 as new potential therapeutic targets. Front. Endocrinol. 3:111
23. Wellendorph P, Johansen LD, Brauner-Osborne H. 2009. Molecular pharmacology of promiscuous seven transmembrane receptors sensing organic nutrients. Mol. Pharmacol. 76:453-65
24. Hudson BD, Ulven T, Milligan G. 2013. The therapeutic potential of allosteric ligands for free fatty acid sensitive GPCRs. Curr. Top. Med. Chem. 13:14-25
25. Mancini AD, Poitout V. 2013. The fatty acid receptor FFA1/GPR40 a decade later: How much do we know? Trends Endocrinol. Metab. 24:398-407
26. Bindels LB, Dewulf EM, Delzenne NM. 2013. GPR43/FFA2: physiopathological relevance and therapeutic prospects. Trends Pharmacol. Sci. 34:226-32
27. Yonezawa T, Kurata R, Yoshida K, Murayama MA, Cui X, Hasegawa A, et al. 2013. Free fatty acids-sensing G protein-coupled receptors in drug targeting and therapeutics. Curr. Med. Chem. 20:3855-71
28. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, et al. 2009. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature 461:1282-86
29. Nilsson C, Swolin-Eide D, Ohlsson C, Eriksson E, Ho HP, et al. 2003. Reductions in adipose tissue and skeletal growth in rat adult offspring after prenatal leptin exposure. J. Endocrinol. 176:13-21
30. Hudson BD, Tikhonova IG, Pandey SK, Ulven T, Milligan G. 2012. Extracellular ionic locks determine variation in constitutive activity and ligand potency between species orthologs of the free fatty acid receptors FFA2 and FFA3. J. Biol. Chem. 287:41195-209
31. Hudson BD, Christiansen E, Tikhonova IG, Grundmann M, Kostenis E, et al. 2012. Chemically engineering ligand selectivity at the free fatty acid receptor 2 based on pharmacological variation between species orthologs. FASEB J. 26:4951-65
32. Hong YH, Nishimura Y, Hishikawa D, Tsuzuki H, Miyahara H, et al. 2005. Acetate and propionate short chain fatty acids stimulate adipogenesis via GPCR43. Endocrinology 146:5092-99
33. Halpern KB, Veprik A, Rubins N, Naaman O, Walker MD. 2012. GPR41 gene expression is mediated by internal ribosome entry site (IRES)-dependent translation of bicistronic mRNA encoding GPR40 and GPR41 proteins. J. Biol. Chem. 287:20154-63
34. Karaki S, Mitsui R, Hayashi H, Kato I, Sugiya H, et al. 2006. Short-chain fatty acid receptor, GPR43, is expressed by enteroendocrine cells and mucosal mast cells in rat intestine. Cell Tissue Res. 324:353-60
35. Tazoe H, Otomo Y, Karaki S, Kato I, Fukami Y, et al. 2009. Expression of short-chain fatty acid receptor GPR41 in the human colon. Biomed. Res. 30:149-56
36. Tazoe H, Otomo Y, Kaji I, Tanaka R, Karaki SI, Kuwahara A. 2008. Roles of short-chain fatty acids receptors, GPR41 and GPR43 on colonic functions. J. Physiol. Pharmacol. 59(Suppl. 2):251-62
37. Samuel BS, Shaito A, Motoike T, Rey FE, Backhed F, et al. 2008. Effects of the gut microbiota on host adiposity are modulated by the short-chain fatty-acid binding G protein-coupled receptor, Gpr41. Proc. Natl. Acad. Sci. USA 105:16767-72
38. Karaki S, Tazoe H, Hayashi H, Kashiwabara H, Tooyama K, et al. 2008. Expression of the short-chain fatty acid receptor, GPR43, in the human colon. J. Mol. Histol. 39:135-42
39. Kaji I, Karaki S, Tanaka R, Kuwahara A. 2011. Density distribution of free fatty acid receptor 2 (FFA2)- expressing and GLP-1-producing enteroendocrine Lcells in human and rat lower intestine, and increased cell numbers after ingestion of fructo-oligosaccharide. J. Mol. Histol. 42:27-38
40. Sykaras AG, Demenis C, Case RM, McLaughlin JT, Smith CP. 2012. Duodenal enteroendocrine I-cells contain mRNA transcripts encoding key endocannabinoid and fatty acid receptors. PLoS ONE 7:e42373
41. Nøhr MK, Pedersen MH, Gille A, Egerod KL, Engelstoft MS, et al. 2013. GPR41/FFAR3 and GPR43/FFAR2 as co-sensors for short chain fatty acids in enteroendocrine cells versus FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology 154:3552-64
42. Xiong Y, Miyamoto N, Shibata K, Valasek MA, Motoike T, et al. 2004. Short-chain fatty acids stimulate leptin production in adipocytes through the G protein-coupled receptor GPR41. Proc. Natl. Acad. Sci. USA 101:1045-50
43. Zaibi MS, Stocker CJ, O'Dowd J, Davies A, Bellahcene M, et al. 2010. Roles of GPR41 and GPR43 in leptin secretory responses of murine adipocytes to short chain fatty acids. FEBS Lett. 584:2381-86
44. Kimura I, Inoue D, Maeda T, Hara T, Ichimura A, et al. 2011. Short-chain fatty acids and ketones directly regulate sympathetic nervous system via G protein-coupled receptor 41 (GPR41). Proc. Natl. Acad. Sci. USA 108:8030-35
45. Senga T, Iwamoto S, Yoshida T, Yokota T, Adachi K, et al. 2003. LSSIG is a novel murine leukocytespecific GPCR that is induced by the activation of STAT3. Blood 101:1185-87
46. Smith PM, Howitt MR, Panikov N, Michaud M, Gallini CA, et al. 2013. The microbial metabolites, short-chain fatty acids, regulate colonic Treg cell homeostasis. Science 341:569-73
47. Topping DL, Clifton PM. 2001. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol. Rev. 81:1031-64
48. Cummings JH, Pomare EW, Branch WJ, Naylor CP, Macfarlane GT. 1987. Short chain fatty acids in human large intestine, portal, hepatic and venous blood. Gut 28:1221-27
49. Wolever TM, Josse RG, Leiter LA, Chiasson JL. 1997. Time of day and glucose tolerance status affect serum short-chain fatty acid concentrations in humans. Metabolism 46:805-11
50. Nilsson AC, Ostman EM, Knudsen KE, Holst JJ, Bjorck IM. 2010. A cereal-based evening meal rich in indigestible carbohydrates increases plasma butyrate the next morning. J. Nutr. 140:1932-36
51. Tarini J, Wolever TM. 2010. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. Appl. Physiol. Nutr. Metab. 35:9-16
52. Siler SQ, Neese RA, Hellerstein MK. 1999. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am. J. Clin. Nutr. 70:928-36
53. Seufert CD, Graf M, Janson G, Kuhn A, Soling HD. 1974. Formation of free acetate by isolated perfused livers from normal, starved and diabetic rats. Biochem. Biophys. Res. Commun. 57:901-9
54. Sakakibara I, Fujino T, Ishii M, Tanaka T, Shimosawa T, et al. 2009. Fasting-induced hypothermia and reduced energy production in mice lacking acetyl-CoA synthetase 2. Cell Metab. 9:191-202
55. Anderson JW, Baird P, Davis RH Jr, Ferreri S, Knudtson M, et al. 2009. Health benefits of dietary fiber. Nutr. Rev. 67:188-205
56. Hou JK, Abraham B, El-Serag H. 2011. Dietary intake and risk of developing inflammatory bowel disease: a systematic review of the literature. Am. J. Gastroenterol. 106:563-73
57. Sina C, Gavrilova O, Forster M, Till A, Derer S, et al. 2009. G protein-coupled receptor 43 is essential for neutrophil recruitment during intestinal inflammation. J. Immunol. 183:7514-22
58. Bellahcene M, O'Dowd JF, Wargent ET, Zaibi MS, Hislop DC, et al. 2013. Male mice that lack the G-protein-coupled receptor GPR41 have low energy expenditure and increased body fat content. Br. J. Nutr. 109:1755-64
59. Tolhurst G, Heffron H, Lam YS, Parker HE, Habib AM, et al. 2012. Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes 61:364-71
60. Lin HV, Frassetto A, Kowalik EJ Jr, Nawrocki AR, Lu MM, et al. 2012. Butyrate and propionate protect against diet-induced obesity and regulate gut hormones via free fatty acid receptor 3-independent mechanisms. PLoS ONE 7:e35240
61. Bjursell M, Admyre T, Goransson M, Marley AE, Smith DM, et al. 2011. Improved glucose control and reduced body fat mass in free fatty acid receptor 2-deficient mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 300:E211-20
62. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, et al. 2010. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142:687-98
63. Briscoe CP, Peat AJ, McKeown SC, Corbett DF, Goetz AS, et al. 2006. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br. J. Pharmacol. 148:619-28
64. Sun Q, Hirasawa A, Hara T, Kimura I, Adachi T, et al. 2010. Structure-activity relationships of GPR120 agonists based on a docking simulation. Mol. Pharmacol. 78:804-10
65. Tikhonova IG, Sum CS, Neumann S, Thomas CJ, Raaka BM, et al. 2007. Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. J. Med. Chem. 50:2981-89
66. Edfalk S, Steneberg P, Edlund H. 2008. Gpr40 is expressed in enteroendocrine cells and mediates free fatty acid stimulation of incretin secretion. Diabetes 57:2280-87
67. Parker HE, Habib AM, Rogers GJ, Gribble FM, Reimann F. 2009. Nutrient-dependent secretion of glucose-dependent insulinotropic polypeptide from primary murine K cells. Diabetologia 52:289-98
68. Liou AP, Lu X, Sei Y, Zhao X, Pechhold S, et al. 2011. TheG-protein-coupled receptor GPR40 directly mediates long-chain fatty acid-induced secretion of cholecystokinin. Gastroenterology 140:903-12
69. Hirasawa A, Itsubo C, Sadakane K, Hara T, Shinagawa S, et al. 2008. Production and characterization of a monoclonal antibody against GPR40 (FFAR1; free fatty acid receptor 1). Biochem. Biophys. Res. Commun. 365:22-28
70. Cartoni C, Yasumatsu K, Ohkuri T, Shigemura N, Yoshida R, et al. 2010. Taste preference for fatty acids is mediated by GPR40 and GPR120. J. Neurosci. 30:8376-82
71. Mieczkowska A, Basle MF, Chappard D, Mabilleau G. 2012. Thiazolidinediones induce osteocyte apoptosis by a G protein-coupled receptor 40-dependent mechanism. J. Biol. Chem. 287:23517-26
72. Wauquier F, Philippe C, Leotoing L, Mercier S, Davicco MJ, et al. 2013. The free fatty acid receptor G protein-coupled receptor 40 (GPR40) protects from bone loss through inhibition of osteoclast differentiation. J. Biol. Chem. 288:6542-51
73. Ma D, Tao B, Warashina S, Kotani S, Lu L, et al. 2007. Expression of free fatty acid receptor GPR40 in the central nervous system of adult monkeys. Neurosci. Res. 58:394-401
74. Nakamoto K, Nishinaka T, Matsumoto K, Kasuya F, Mankura M, et al. 2012. Involvement of the long-chain fatty acid receptor GPR40 as a novel pain regulatory system. Brain Res. 1432:74-83
75. Opara EC, Garfinkel M, Hubbard VS, Burch WM, Akwari OE. 1994. Effect of fatty acids on insulin release: role of chain length and degree of unsaturation. Am. J. Physiol. 266:E635-39
76. Stein DT, Stevenson BE, Chester MW, Basit M, Daniels MB, et al. 1997. The insulinotropic potency of fatty acids is influenced profoundly by their chain length and degree of saturation. J. Clin. Investig. 100:398-403
77. McGarry JD, Dobbins RL. 1999. Fatty acids, lipotoxicity and insulin secretion. Diabetologia 42:128-38
78. Tomita T, Masuzaki H, Iwakura H, Fujikura J, Noguchi M, et al. 2006. Expression of the gene for a membrane-bound fatty acid receptor in the pancreas and islet cell tumours in humans: evidence for GPR40 expression in pancreatic beta cells and implications for insulin secretion. Diabetologia 49:962-68
79. Steneberg P, Rubins N, Bartoov-Shifman R, Walker MD, Edlund H. 2005. The FFA receptor GPR40 links hyperinsulinemia, hepatic steatosis, and impaired glucose homeostasis in mouse. Cell Metab. 1:245-58
80. Shapiro H, Shachar S, Sekler I, Hershfinkel M, Walker MD. 2005. Role of GPR40 in fatty acid action on the beta cell line INS-1E. Biochem. Biophys. Res. Commun. 335:97-104
81. Latour MG, Alquier T, Oseid E, Tremblay C, Jetton TL, et al. 2007. GPR40 is necessary but not sufficient for fatty acid stimulation of insulin secretion in vivo. Diabetes 56:1087-94
82. Kebede M, Alquier T, Latour MG, Semache M, Tremblay C, Poitout V. 2008. The fatty acid receptor GPR40 plays a role in insulin secretion in vivo after high-fat feeding. Diabetes 57:2432-37
83. Nagasumi K, Esaki R, Iwachidow K, Yasuhara Y, Ogi K, et al. 2009. Overexpression of GPR40 in pancreatic β-cells augments glucose-stimulated insulin secretion and improves glucose tolerance in normal and diabetic mice. Diabetes 58:1067-76
84. Alquier T, Peyot ML, Latour MG, Kebede M, Sorensen CM, et al. 2009. Deletion of GPR40 impairs glucose-induced insulin secretion in vivo in mice without affecting intracellular fuel metabolism in islets. Diabetes 58:2607-15
85. 2+ channel and link to insulin release. Am. J. Physiol. Endocrinol. Metab. 289:E670-77
86. Morgan NG, Dhayal S. 2009. G-protein coupled receptors mediating long chain fatty acid signalling in the pancreatic beta-cell. Biochem. Pharmacol. 78:1419-27
87. Kebede M, Ferdaoussi M, Mancini A, Alquier T, Kulkarni RN, et al. 2012. Glucose activates free fatty acid receptor 1 gene transcription via phosphatidylinositol-3-kinase-dependent O-GlcNAcylation of pancreas-duodenum homeobox-1. Proc. Natl. Acad. Sci. USA 109:2376-81
88. Del Guerra S, Bugliani M, D'Aleo V, Del Prato S, Boggi U, et al. 2010. G-protein-coupled receptor 40 (GPR40) expression and its regulation in human pancreatic islets: the role of type 2 diabetes and fatty acids. Nutr. Metab. Cardiovasc. Dis. 20:22-25
89. Tan CP, Feng Y, Zhou YP, Eiermann GJ, Petrov A, et al. 2008. Selective small-molecule agonists of G protein-coupled receptor 40 promote glucose-dependent insulin secretion and reduce blood glucose in mice. Diabetes 57:2211-19
90. Lan H, Hoos LM, Liu L, Tetzloff G, Hu W, et al. 2008. Lack of FFAR1/GPR40 does not protect mice from high-fat diet-induced metabolic disease. Diabetes 57:2999-3006
91. Song F, Lu S, Gunnet J, Xu JZ, Wines P, et al. 2007. Synthesis and biological evaluation of 3-aryl-3-(4-phenoxy)-propionic acid as a novel series of G protein-coupled receptor 40 agonists. J. Med. Chem. 50:2807-17
92. Reimann F, Habib AM, Tolhurst G, Parker HE, Rogers GJ, Gribble FM. 2008. Glucose sensing in L cells: a primary cell study. Cell Metab. 8:532-39
93. Gotoh C, Hong YH, Iga T, Hishikawa D, Suzuki Y, et al. 2007. The regulation of adipogenesis through GPR120. Biochem. Biophys. Res. Commun. 354:591-97
94. Matsumura S, Eguchi A, Mizushige T, Kitabayashi N, Tsuzuki S, et al. 2009. Colocalization of GPR120 with phospholipase-Cβ2 and α-gustducin in the taste bud cells in mice. Neurosci. Lett. 450:186-90
95. Moore K, Zhang Q, Murgolo N, Hosted T, Duffy R. 2009. Cloning, expression, and pharmacological characterization of the GPR120 free fatty acid receptor from cynomolgus monkey: comparison with human GPR120 splice variants. Comp. Biochem. Physiol. B 154:419-26
96. Watson SJ, Brown AJ, Holliday N. 2012. Differential signalling by splice variants of the human free fatty acid receptor, GPR120. Mol. Pharmacol. 81:631-42
97. De Caterina R. 2011. n-3 fatty acids in cardiovascular disease. N. Engl. J. Med. 364:2439-50
98. Godinot N, Yasumatsu K, Barcos ME, Pineau N, Ledda M, et al. 2013. Activation of tongue-expressed GPR40 and GPR120 by non caloric agonists is not sufficient to drive preference in mice. Neuroscience 250:20-30
99. Galindo MM, Voigt N, Stein J, van Lengerich J, Raguse JD, et al. 2012. G protein-coupled receptors in human fat taste perception. Chem. Senses 37:123-39
100. Matsumura S, Mizushige T, Yoneda T, Iwanaga T, Tsuzuki S, et al. 2007. GPR expression in the rat taste bud relating to fatty acid sensing. Biomed. Res. 28:49-55
101. Shin YK, Martin B, Golden E, Dotson CD, Maudsley S, et al. 2008. Modulation of taste sensitivity by GLP-1 signaling. J. Neurochem. 106:455-63
102. Martin C, Passilly-Degrace P, Chevrot M, Ancel D, Sparks SM, et al. 2012. Lipid-mediated release of GLP-1 by mouse taste buds from circumvallate papillae: putative involvement of GPR120 and impact on taste sensitivity. J. Lipid Res. 53:2256-65
103. Lu X, Zhao X, Feng J, Liou AP, Anthony S, et al. 2012. Postprandial inhibition of gastric ghrelin secretion by long-chain fatty acid through GPR120 in isolated gastric ghrelin cells and mice. Am. J. Physiol. Gastrointest. Liver Physiol. 303:G367-76
104. Janssen S, Laermans J, Iwakura H, Tack J, Depoortere I. 2012. Sensing of fatty acids for octanoylation of ghrelin involves a gustatory G-protein. PLoS ONE 7:e40168
105. Cummings DE, Overduin J. 2007. Gastrointestinal regulation of food intake. J. Clin. Investig. 117:13-23
106. Cintra DE, Ropelle ER, Moraes JC, Pauli JR, Morari J, et al. 2012. Unsaturated fatty acids revert diet-induced hypothalamic inflammation in obesity. PLoS ONE 7:e30571
107. Paschos GK, Ibrahim S, Song WL, Kunieda T, Grant G, et al. 2012. Obesity in mice with adipocytespecific deletion of clock component Arntl. Nat. Med. 18:1768-77
108. Yan Y, Jiang W, Spinetti T, Tardivel A, Castillo R, et al. 2013. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38:1154-63
109. Ichimura A, Hirasawa A, Poulain-Godefroy O, Bonnefond A, Hara T, et al. 2012. Dysfunction of lipid sensor GPR120 leads to obesity in both mouse and human. Nature 483:350-54
110. Wang J, Wu X, Simonavicius N, Tian H, Ling L. 2006. Medium-chain fatty acids as ligands for orphan G protein-coupled receptor GPR84. J. Biol. Chem. 281:34457-64
111. Suzuki M, Takaishi S, Nagasaki M, Onozawa Y, Iino I, et al. 2013. Medium-chain fatty acid sensing receptor, GPR84, is a proinflammatory receptor. J. Biol. Chem. 288:10684-91
112. Venkataraman C, Kuo F. 2005. The G-protein coupled receptor, GPR84 regulates IL-4 production by T lymphocytes in response to CD3 crosslinking. Immunol. Lett. 101:144-53
113. Brown AJ, Jupe S, Briscoe CP. 2005. A family of fatty acid binding receptors. DNA Cell Biol. 24:54-61
114. Liaw CW, Connolly DT. 2009. Sequence polymorphisms provide a common consensus sequence for GPR41 and GPR42. DNA Cell Biol. 28:555-60
115. Luo J, Swaminath G, Brown SP, Zhang J, Guo Q, et al. 2012. A potent class of GPR40 full agonists engages the enteroinsular axis to promote glucose control in rodents. PLoS ONE 7:e46300
116. Lin DC, Zhang J, Zhuang R, Li F, Nguyen K, et al. 2011. AMG 837: a novel GPR40/FFA1 agonist that enhances insulin secretion and lowers glucose levels in rodents. PLoS ONE 6:e27270
117. Negoro N, Sasaki S, Mikami S, Ito M, Suzuki M, et al. 2010. Discovery of TAK-875: a potent, selective, and orally bioavailable GPR40 agonist. ACS Med. Chem. Lett. 1:290-94
118. Burant CF, Viswanathan P, Marcinak J, Cao C, Vakilynejad M, et al. 2012. TAK-875 versus placebo or glimepiride in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 379:1403-11
119. Tikhonova IG, Sum CS, Neumann S, Engel S, Raaka BM, et al. 2008. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. J. Med. Chem. 51:625-33
120. Humphries PS, Benbow JW, Bonin PD, Boyer D, Doran SD, et al. 2009. Synthesis and SAR of 1,2,3,4-tetrahydroisoquinolin-1-ones as novel G-protein-coupled receptor 40 (GPR40) antagonists. Bioorg. Med. Chem. Lett. 19:2400-3
121. Hu H, He LY, Gong Z, Li N, Lu YN, et al. 2009. A novel class of antagonists for the FFAs receptor GPR40. Biochem. Biophys. Res. Commun. 390:557-63
122. Lee T, Schwandner R, Swaminath G, Weiszmann J, Cardozo M, et al. 2008. Identification and functional characterization of allosteric agonists for the Gprotein-coupled receptor FFA2. Mol. Pharmacol. 74:1599-609
123. Swaminath G, Jaeckel P, Guo Q, Cardozo M, Weiszmann J, et al. 2011. Mutational analysis of G-protein coupled receptor-FFA2. Biochem. Biophys. Res. Commun. 405:122-27
124. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, et al. 2010. The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg. Med. Chem. Lett. 20:493-98
125. Hoveyda H, Brantis CE, Detheuil G, Zoute L, Schils D, Bernard J. 2010. Compounds, pharmaceutical composition and methods for use in treating metabolic disorders. WO Patent No. 2010/066682
126. Hoveyda H, Brantis CE, Detheuil G, Zoute L, Schils D, Bernard J. 2011. Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases. WO Patent No. 2011/076734
127. Hoveyda H, Brantis CE, Detheuil G, Zoute L, Schils D, Fraser G. 2011. Compounds, pharmaceutical composition and methods for use in treating gastrointestinal disorders. WO Patent No. 2011/076732
128. Hoveyda H, Zoute L, Lenoir F. 2011. Azepanes, azocanes and related compounds as GPR43modulators and their preparation and use for the treatment of inflammatory, gastrointestinal and metabolic disorders. WO Patent No. 2011/151436
129. Saniere LRM, Pizonero MR, Triballeau N, Vandeghinste NER, De VSIJ, et al. 2012. Preparation of azetidine derivatives as GPR43 antagonists useful in the treatment of metabolic and inflammatory diseases. WO Patent No. 2012/098033
130. Brantis CE, Ooms F, Bernard J. 2011. Novel amino acid derivatives and their use as GPR43 receptor modulators. WO Patent No. 2011/092284(A1)
131. Suzuki K, Kumanogoh A, Kikutani H. 2008. Semaphorins and their receptors in immune cell interactions. Nat. Immunol. 9:17-23
132. Shimpukade B, Hudson BD, Hovgaard CK, Milligan G, Ulven T. 2012. Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55:4511-15
133. Shi DF, Song J, Ma J, Novack A, Pham P, et al. 2011. GPR120 receptor agonists and uses thereof. US Patent No. 2011/313003(A1)
134. Ishikawa M, Haketa T, Nakama C, Nishimura T, Shibata J, Shimamura T, Yamakawa T. 2009. Novel isoxazole derivative. WO Patent No. 2009/147990
135. Ahmed K, Tunaru S, Langhans CD, Hanson J, Michalski CW, et al. 2009. Deorphanization of GPR109B as a receptor for the β-oxidation intermediate 3-OH-octanoic acid and its role in the regulation of lipolysis. J. Biol. Chem. 284:21928-33
136. Osnes JB, Hermansen L. 1972. Acid-base balance after maximal exercise of short duration. J. Appl. Physiol. 32:59-63
137. Owen OE, Felig P, Morgan AP, Wahren J, Cahill GF Jr. 1969. Liver and kidney metabolism during prolonged starvation. J. Clin. Investig. 48:574-83
138. Kuei C, Yu J, Zhu J, Wu J, Zhang L, et al. 2011. Study of GPR81, the lactate receptor, from distant species identifies residues and motifs critical for GPR81 functions. Mol. Pharmacol. 80:848-58
139. Zellner C, Pullinger CR, Aouizerat BE, Frost PH, Kwok PY, et al. 2005. Variations in human HM74 (GPR109B) and HM74A (GPR109A) niacin receptors. Hum. Mutat. 25:18-21
140. Ahmed K, Tunaru S, Tang C, Muller M, Gille A, et al. 2010. An autocrine lactate loop mediates insulindependent inhibition of lipolysis through GPR81. Cell Metab. 11:311-19
141. Digby JE, Martinez F, Jefferson A, Ruparelia N, Chai J, et al. 2012. Anti-inflammatory effects of nicotinic acid in human monocytes are mediated by GPR109A dependent mechanisms. Arterioscler. Thromb. Vasc. Biol. 32:669-76
142. Singh N, Thangaraju M, Prasad PD, Martin PM, Lambert NA, et al. 2010. Blockade of dendritic cell development by bacterial fermentation products butyrate and propionate through a transporter (Slc5a8)- dependent inhibition of histone deacetylases. J. Biol. Chem. 285:27601-8
143. Zandi-Nejad K, Takakura A, Jurewicz M, Chandraker AK, Offermanns S, et al. 2013. The role of HCA2 (GPR109A) in regulating macrophage function. FASEB J. 27:4366-74
144. Tunaru S, Kero J, Schaub A, Wufka C, Blaukat A, et al. 2003. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect. Nat. Med. 9:352-55
145. Soga T, Kamohara M, Takasaki J, Matsumoto S, Saito T, et al. 2003. Molecular identification of nicotinic acid receptor. Biochem. Biophys. Res. Commun. 303:364-69
146. Wise A, Foord SM, Fraser NJ, Barnes AA, Elshourbagy N, et al. 2003. Molecular identification of high and low affinity receptors for nicotinic acid. J. Biol. Chem. 278:9869-74
147. Ge H, Weiszmann J, Reagan JD, Gupte J, Baribault H, et al. 2008. Elucidation of signaling and functional activities of an orphan GPCR, GPR81. J. Lipid Res. 49:797-803
148. Jeninga EH, Bugge A, Nielsen R, Kersten S, Hamers N, et al. 2009. Peroxisome proliferator-activated receptor γ regulates expression of the anti-lipolytic G-protein-coupled receptor 81 (GPR81/Gpr81). J. Biol. Chem. 284:26385-93
149. Wanders D, Graff EC, Judd RL. 2012. Effects of high fat diet on GPR109A and GPR81 gene expression. Biochem. Biophys. Res. Commun. 425:278-83
150. Feingold KR, Moser A, Shigenaga JK, Grunfeld C. 2011. Inflammation inhibits GPR81 expression in adipose tissue. Inflamm. Res. 60:991-95
151. Regard JB, Sato IT, Coughlin SR. 2008. Anatomical profiling of G protein-coupled receptor expression. Cell 135:561-71
152. Di Girolamo M, Newby FD, Lovejoy J. 1992. Lactate production in adipose tissue: a regulated function with extra-adipose implications. FASEB J. 6:2405-12
153. Qvisth V, Hagstrom-Toft E, Moberg E, Sjoberg S, Bolinder J. 2007. Lactate release from adipose tissue and skeletal muscle in vivo: defective insulin regulation in insulin-resistant obese women. Am. J. Physiol. Endocrinol. Metab. 292:E709-14
154. Jansson PA, Larsson A, Smith U, Lonnroth P. 1994. Lactate release from the subcutaneous tissue in lean and obese men. J. Clin. Investig. 93:240-46
155. Schaub A, Futterer A, Pfeffer K. 2001. PUMA-G, an IFN-γ-inducible gene in macrophages is a novel member of the seven transmembrane spanning receptor superfamily. Eur. J. Immunol. 31:3714-25
156. Benyo Z, Gille A, Kero J, Csiky M, Suchankova MC, et al. 2005.GPR109A(PUMA-G/HM74A)mediates nicotinic acid-induced flushing. J. Clin. Investig. 115:3634-40
157. Maciejewski-Lenoir D, Richman JG, Hakak Y, Gaidarov I, Behan DP, Connolly DT. 2006. Langerhans cells release prostaglandin D2 in response to nicotinic acid. J. Investig. Dermatol. 126:2637-46
158. Kostylina G, Simon D, Fey MF, Yousefi S, Simon HU. 2008. Neutrophil apoptosis mediated by nicotinic acid receptors (GPR109A). Cell Death Differ. 15:134-42
159. Knowles HJ, Poole RT, Workman P, Harris AL. 2006. Niacin induces PPARγexpression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways. Biochem. Pharmacol. 71:646-56
160. Thangaraju M, Cresci GA, Liu K, Ananth S, Gnanaprakasam JP, et al. 2009. GPR109A is a G-proteincoupled receptor for the bacterial fermentation product butyrate and functions as a tumor suppressor in colon. Cancer Res. 69:2826-32
161. Martin K, Weiss S, Metharom P, Schmeckpeper J, Hynes B, et al. 2009. Thrombin stimulates smooth muscle cell differentiation from peripheral blood mononuclear cells via protease-activated receptor-1, Rho A, and myocardin. Circ. Res. 105:214-18
162. Cresci GA, Thangaraju M, Mellinger JD, Liu K, Ganapathy V. 2010. Colonic gene expression in conventional and germ-free mice with a focus on the butyrate receptor GPR109A and the butyrate transporter SLC5A8. J. Gastrointest. Surg. 14:449-61
163. Tang H, Lu JY, Zheng X, Yang Y, Reagan JD. 2008. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem. Biophys. Res. Commun. 375:562-65
164. Hanson J, Gille A, Zwykiel S, Lukasova M, Clausen BE, et al. 2010. Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice. J. Clin. Investig. 120:2910-19
165. Senior B, Loridan L. 1968. Direct regulatory effect of ketones on lipolysis and on glucose concentrations in man. Nature 219:83-84
166. Lukasova M, Malaval C, Gille A, Kero J, Offermanns S. 2011. Nicotinic acid inhibits progression of atherosclerosis in mice through its receptor GPR109A expressed by immune cells. J. Clin. Investig. 121:1163-73
167. Singh V, Jamwal S, Jain R, Verma P, Gokhale R, Rao KV. 2012. Mycobacterium tuberculosis-driven targeted recalibration of macrophage lipid homeostasis promotes the foamy phenotype. Cell Host Microbe 12:669-81
168. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, et al. 2010. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. Cell 140:731-43
169. Carlson LA. 2005. Nicotinic acid: the broad-spectrum lipid drug. A 50th
170. Gille A, Bodor ET, Ahmed K, Offermanns S. 2008. Nicotinic acid: pharmacological effects and mechanisms of action. Annu. Rev. Pharmacol. Toxicol. 48:79-106
171. Hernandez M, Wright SD, Cai TQ. 2007. Critical role of cholesterol ester transfer protein in nicotinic acid-mediated HDL elevation in mice. Biochem. Biophys. Res. Commun. 355:1075-80
172. van der Hoorn JW, de Haan W, Berbee JF, Havekes LM, Jukema JW, et al. 2008. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3 Leiden. CETP mice. Arterioscler. Thromb. Vasc. Biol. 28:2016-22
173. Lauring B, Taggart AK, Tata JR, Dunbar R, Caro L, et al. 2012. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression. Sci. Transl. Med. 4:148ra15
174. Offermanns S. 2012. It ain't over 'til the fat lady sings. Sci. Transl. Med. 4:148fs30
175. Wu BJ, Yan L, Charlton F, Witting P, Barter PJ, Rye KA. 2010. Evidence that niacin inhibits acute vascular inflammation and improves endothelial dysfunction independent of changes in plasma lipids. Arterioscler. Thromb. Vasc. Biol. 30:968-75
176. Benyó Z, Gille A, Bennett CL, Clausen BE, Offermanns S. 2006. Nicotinic acid-induced flushing is mediated by activation of epidermal Langerhans cells. Mol. Pharmacol. 70:1844-49
177. 2 (GPR109A) in nicotinic acid and fumaric acid ester-induced effects on the skin. Pharmacol. Ther. 136:1-7
178. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, et al. 2011. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N. Engl. J. Med. 365:2255-67
179. HPS2-THRIVE Collab. Group. 2013. HPS2-THRIVE randomized placebo-controlled trial in 25,673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment. Eur. Heart J. 34:1279-91
180. Irukayama-Tomobe Y, Tanaka H, Yokomizo T, Hashidate-Yoshida T, Yanagisawa M, Sakurai T. 2009. Aromatic D-amino acids act as chemoattractant factors for human leukocytes through a G proteincoupled receptor, GPR109B. Proc. Natl. Acad. Sci. USA 106:3930-34
181. Nomura H, Nielsen BW, Matsushima K. 1993. Molecular cloning of cDNAs encoding a LD78 receptor and putative leukocyte chemotactic peptide receptors. Int. Immunol. 5:1239-49
182. Yousefi S, Cooper PR, Mueck B, Potter SL, Jarai G. 2000. cDNA representational difference analysis of human neutrophils stimulated by GM-CSF. Biochem. Biophys. Res. Commun. 277:401-9
183. Costa CG, Dorland L, Holwerda U, de Almeida IT, Poll-The BT, et al. 1998. Simultaneous analysis of plasma free fatty acids and their 3-hydroxy analogs in fatty acid β-oxidation disorders. Clin. Chem. 44:463-71
184. Liu C, Kuei C, Zhu J, Yu J, Zhang L, et al. 2012. 3,5-Dihydroxybenzoic acid, a specific agonist for HCA1, inhibits lipolysis in adipocytes. J. Pharmacol. Exp. Ther. 341:794-801
185. Boatman PD, Johnson BR, Jung JK, Kasem M, Schrader TO, et al. 2010. 3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders. WO Patent No. 2010/030360(A1)
186. Jung JK, Johnson BR, Duong T, Decaire M, Uy J, et al. 2007. Analogues of acifran: agonists of the high and low affinity niacin receptors, GPR109a and GPR109b. J. Med. Chem. 50:1445-48
187. van Herk T, Brussee J, van den Nieuwendijk AMCH, van der Klein PAM, IJzerman AP, et al. 2003. Pyrazole derivatives as partial agonists for the nicotinic acid receptor. J. Med. Chem. 46:3945-51
188. Semple G, Skinner PJ, Gharbaoui T, Shin YJ, Jung JK, et al. 2008. 3-(1H-tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): a partial agonist of the nicotinic acid receptor, G-protein coupled receptor 109a, with antilipolytic but no vasodilatory activity in mice. J. Med. Chem. 51:5101-8
189. Boatman PD, Lauring B, Schrader TO, Kasem M, Johnson BR, et al. 2012. (1a R,5aR)1a,3,5,5a-Tetrahydro-1H-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid (MK-1903): a potent GPR109a agonist that lowers free fatty acids in humans. J. Med. Chem. 55:3644-66
190. Shen HC, Colletti SL. 2010. High-affinity niacin receptor GPR109A agonists. Annu. Rep. Med. Chem. 45:72-94
191. Palani A, Rao AU, Chen X, Huang XH, Su J, et al. 2012. Discovery of SCH 900271, a potent nicotinic acid receptor agonist for the treatment of dyslipidemia. ACS Med. Chem. Lett. 3:63-68
192. Lukasova M, Hanson J, Tunaru S, Offermanns S. 2011. Nicotinic acid (niacin): new lipid-independent mechanisms of action and therapeutic potentials. Trends Pharmacol. Sci. 32:700-7
193. Rostami Yazdi M, Mrowietz U. 2008. Fumaric acid esters. Clin. Dermatol. 26:522-26
194. Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N. Engl. J. Med. 367:1098-107
195. Fox RJ, Miller DH, Phillips JT, Hutchinson M, Havrdova E, et al. 2012. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N. Engl. J. Med. 367:1087-97
196. Ma J, Cheon HS, Kishi Y. 2007. Chiral aggregates formed from methylated tetraenoic fatty acids: formation of both antipodes of chiral aggregates from a single enantiomer and time-dependent stereomutation. Org. Lett. 9:319-22
197. Engelstoft MS, Park W, Sakata I, Kristensen LV, Husted AS, et al. 2013. Seven transmembrane G protein-coupled receptor repertoire of gastric ghrelin cells. Mol. Metab. In press
198. Vinolo MA, Ferguson GJ, Kulkarni S, Damoulakis G, Anderson K, et al. 2011. SCFAs induce mouse neutrophil chemotaxis through the GPR43 receptor. PLoS ONE 6:e21205
199. Miyauchi S, Hirasawa A, Iga T, Liu N, Itsubo C, et al. 2009. Distribution and regulation of protein expression of the free fatty acid receptor GPR120. Naunyn Schmiedebergs Arch. Pharmacol. 379:427-34
200. Tunaru S, Lattig J, Kero J, Krause G, Offermanns S. 2005. Characterization of determinants of ligand binding to the nicotinic acid receptor GPR109A (HM74A/PUMA-G). Mol. Pharmacol. 68:1271-80
201. Wang Y, Jiao X, Kayser F, Liu J, Wang Z, et al. 2010. The first synthetic agonists of FFA2: discovery and SAR of phenylacetamides as allosteric modulators. Bioorg. Med. Chem. Lett. 20:493-98
202. Hudson BD, Due-Hansen ME, Christiansen E, Hansen AM, Mackenzie AE, et al. 2013. Defining the molecular basis for the first potent and selective orthosteric agonists of the FFA2 free fatty acid receptor. J. Biol. Chem. 288:17296-312
203. 1/GPR40), a potential target for the treatment of type II diabetes. J. Med. Chem. 51:7061-64
204. Christiansen E, Due-Hansen ME, Urban C, Grundmann M, Schmidt J, et al. 2013. Discovery of a potent and selective free fatty acid receptor 1 agonist with low lipophilicity and high oral bioavailability. J. Med. Chem. 56:982-92
205. Shen HC, Ding FX, Raghavan S, Deng Q, Luell S, et al. 2010. Discovery of a biaryl cyclohexene carboxylic acid (MK-6892): a potent and selective high affinity niacin receptor full agonist with reduced flushing profiles in animals as a preclinical candidate. J. Med. Chem. 53:2666-70
206. Skinner PJ, Webb PJ, Sage CR, Dang TH, Pride CC, et al. 2009. 5-N, N-Disubstituted 5-aminopyrazole-3-carboxylic acids are highly potent agonists of GPR109b. Bioorg. Med. Chem. Lett. 19:4207-9
207. Semple G, Skinner PJ, Cherrier MC, Webb PJ, Sage CR, et al. 2006. 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b. J. Med. Chem. 49:1227-30